GlycoMimetics (GLYC) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
March 29, 2023 7:00 AM EDTSignificant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) Interim utility analysis used high statistical threshold and resulted in independent Data Monitoring Committee (DMC) recommending trial continue to final survival events, projected to occur in the first half of 2024; DMC also expressed no safety concerns about the trial Cash and cash equivalents expected to fund current operations to year end 2024 Conference call and webcast today at 8:30 a.m. ET
ROCKVILLE, Md.--(BUSINESS... More
